Search

Summary: Long-chain Polyunsaturated Fatty Acids (PUFAs) especially n-3 series such as Omega-3, Docosahexaenoic Acid (DHA), and Eicosapentaenoic Acid perform as necessary dietary supplements to consider the well-being of human health. Notably, these FAs evoked specific protein targeting biogenesis pathways in the cytosol that prevents various human disorders likewise; as coronary heart disease, inflammatory disease, liver problems, diabetes, brain development, eye problems, cancer therapy as well as therapy in COVID-19. In the protein regulation, PUFAs alter the composition of membrane lipids, modulation of cyclooxygenase, activation of SIRT1/AMPK, control intracellular metabolism, control the signal transduction along with gene expression, and regulates transcription factors like SREBF1c as well as nuclear receptors HNF-4, GPCR, PPAR, LXR, TLR-4, etc. Thus, the present article focuses on the potential cytotoxic therapeutic role and pleiotropic effects of n-3 PUFAs against chronic inflammations, platelet aggregation, coronary diseases, retinal disorder, and cancer cell proliferation in human body.

SARS-CoV-2 is spreading globally at a rapid pace. To contain its spread and prevent further fatalities, the development of a vaccine against SARS-CoV-2 is an urgent prerequisite. Thus, in this article, by utilizing the in-silico approach, a vaccine candidate for SARS-CoV-2 has been proposed. Moreover, the effectiveness and safety measures of our proposed epitopic vaccine candidate have been evaluated by in-silico tools and servers (AllerTOP and AllergenFP servers). We observed that the vaccine candidate has no allergenicity and successfully combined with Toll-like receptor (TLR) protein to elicit an inflammatory immune response. Stable, functional mobility of the vaccine-TLR protein binding interface was confirmed by the Normal Mode Analysis. The in-silico cloning model demonstrated the efficacy of the construct vaccine along with the identified epitopes against SARS-CoV-2. Taken together, our proposed in-silico vaccine candidate has potent efficacy against COVID-19 infection, and successive research work might validate its effectiveness in in vitro and in vivo models.

Abstract In 2007, the Michigan Institute for Clinical and Health Research (MICHR) at the University of Michigan received a Clinical and Translational Science Award (CTSA). Within MICHR, the Community Engagement (CE) program supports partnership efforts between researchers, practitioners, and community‐based organizations in specific focal communities throughout Michigan. A key component of the CE program is the Community Engagement Coordinating Council, a group that provides input and guidance on program priorities, strategic planning, and reviews pilot funding proposals for community–academic partnerships. This paper will describe a unique MICHR pilot funding mechanism for Community–University Research Partnerships (CURES) with an emphasis on the ways that community partners are involved in the review process, as well as the benefits, challenges, and insights gained over 5 years of pilot review. There is a growing need for community involvement and expertise in review of funding proposals for community‐engaged research at both institutional and federal levels. The CURES pilot review process is one example of an institutional effort to engage community partners in university funding decisions and has demonstrated clear benefit toward accomplishing the aims of the CTSA.